IBDEI0CX ; ; 19-NOV-2014
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;OCT 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,17316,2)
 ;;=^267981
 ;;^UTILITY(U,$J,358.3,17317,0)
 ;;=282.7^^88^937^77
 ;;^UTILITY(U,$J,358.3,17317,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,17317,1,4,0)
 ;;=4^282.7
 ;;^UTILITY(U,$J,358.3,17317,1,5,0)
 ;;=5^Hemoglobin C Disease
 ;;^UTILITY(U,$J,358.3,17317,2)
 ;;=^87629
 ;;^UTILITY(U,$J,358.3,17318,0)
 ;;=283.9^^88^937^79
 ;;^UTILITY(U,$J,358.3,17318,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,17318,1,4,0)
 ;;=4^283.9
 ;;^UTILITY(U,$J,358.3,17318,1,5,0)
 ;;=5^Hemolytic Anemia,Acquired
 ;;^UTILITY(U,$J,358.3,17318,2)
 ;;=^7071
 ;;^UTILITY(U,$J,358.3,17319,0)
 ;;=283.0^^88^937^80
 ;;^UTILITY(U,$J,358.3,17319,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,17319,1,4,0)
 ;;=4^283.0
 ;;^UTILITY(U,$J,358.3,17319,1,5,0)
 ;;=5^Hemolytic Anemia,Autoimmune
 ;;^UTILITY(U,$J,358.3,17319,2)
 ;;=^7079
 ;;^UTILITY(U,$J,358.3,17320,0)
 ;;=282.9^^88^937^81
 ;;^UTILITY(U,$J,358.3,17320,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,17320,1,4,0)
 ;;=4^282.9
 ;;^UTILITY(U,$J,358.3,17320,1,5,0)
 ;;=5^Hemolytic Anemia,Hereditary
 ;;^UTILITY(U,$J,358.3,17320,2)
 ;;=^56578
 ;;^UTILITY(U,$J,358.3,17321,0)
 ;;=283.19^^88^937^82
 ;;^UTILITY(U,$J,358.3,17321,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,17321,1,4,0)
 ;;=4^283.19
 ;;^UTILITY(U,$J,358.3,17321,1,5,0)
 ;;=5^Hemolytic Anemia,Microang
 ;;^UTILITY(U,$J,358.3,17321,2)
 ;;=^293664
 ;;^UTILITY(U,$J,358.3,17322,0)
 ;;=280.9^^88^937^86
 ;;^UTILITY(U,$J,358.3,17322,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,17322,1,4,0)
 ;;=4^280.9
 ;;^UTILITY(U,$J,358.3,17322,1,5,0)
 ;;=5^Iron Defic Anemia,Unspec
 ;;^UTILITY(U,$J,358.3,17322,2)
 ;;=^276946
 ;;^UTILITY(U,$J,358.3,17323,0)
 ;;=285.1^^88^937^84
 ;;^UTILITY(U,$J,358.3,17323,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,17323,1,4,0)
 ;;=4^285.1
 ;;^UTILITY(U,$J,358.3,17323,1,5,0)
 ;;=5^Iron Defic Anemia d/t Acute Blood Loss
 ;;^UTILITY(U,$J,358.3,17323,2)
 ;;=^267986
 ;;^UTILITY(U,$J,358.3,17324,0)
 ;;=280.0^^88^937^85
 ;;^UTILITY(U,$J,358.3,17324,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,17324,1,4,0)
 ;;=4^280.0
 ;;^UTILITY(U,$J,358.3,17324,1,5,0)
 ;;=5^Iron Defic Anemia d/t Chronic Blood Loss
 ;;^UTILITY(U,$J,358.3,17324,2)
 ;;=^267971
 ;;^UTILITY(U,$J,358.3,17325,0)
 ;;=281.9^^88^937^107
 ;;^UTILITY(U,$J,358.3,17325,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,17325,1,4,0)
 ;;=4^281.9
 ;;^UTILITY(U,$J,358.3,17325,1,5,0)
 ;;=5^Nutritional Anemia
 ;;^UTILITY(U,$J,358.3,17325,2)
 ;;=^123801
 ;;^UTILITY(U,$J,358.3,17326,0)
 ;;=281.0^^88^937^123
 ;;^UTILITY(U,$J,358.3,17326,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,17326,1,4,0)
 ;;=4^281.0
 ;;^UTILITY(U,$J,358.3,17326,1,5,0)
 ;;=5^Vit B12 Deficiency (Pernicious Anemia)
 ;;^UTILITY(U,$J,358.3,17326,2)
 ;;=^7161
 ;;^UTILITY(U,$J,358.3,17327,0)
 ;;=282.60^^88^937^111
 ;;^UTILITY(U,$J,358.3,17327,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,17327,1,4,0)
 ;;=4^282.60
 ;;^UTILITY(U,$J,358.3,17327,1,5,0)
 ;;=5^Sickle-Cell Anemia
 ;;^UTILITY(U,$J,358.3,17327,2)
 ;;=^7188
 ;;^UTILITY(U,$J,358.3,17328,0)
 ;;=282.62^^88^937^112
 ;;^UTILITY(U,$J,358.3,17328,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,17328,1,4,0)
 ;;=4^282.62
 ;;^UTILITY(U,$J,358.3,17328,1,5,0)
 ;;=5^Sickle-Cell With Crisis
 ;;^UTILITY(U,$J,358.3,17328,2)
 ;;=^267982
 ;;^UTILITY(U,$J,358.3,17329,0)
 ;;=281.1^^88^937^124
 ;;^UTILITY(U,$J,358.3,17329,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,17329,1,4,0)
 ;;=4^281.1
 ;;^UTILITY(U,$J,358.3,17329,1,5,0)
 ;;=5^Vit B12 Deficiency(Dietary)
 ;;^UTILITY(U,$J,358.3,17329,2)
 ;;=^267974
 ;;^UTILITY(U,$J,358.3,17330,0)
 ;;=286.7^^88^937^54
 ;;^UTILITY(U,$J,358.3,17330,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,17330,1,4,0)
 ;;=4^286.7
 ;;^UTILITY(U,$J,358.3,17330,1,5,0)
 ;;=5^Coagulation Defect(Any),Acquired
 ;;^UTILITY(U,$J,358.3,17330,2)
 ;;=^2235
 ;;^UTILITY(U,$J,358.3,17331,0)
 ;;=289.9^^88^937^120
 ;;^UTILITY(U,$J,358.3,17331,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,17331,1,4,0)
 ;;=4^289.9
 ;;^UTILITY(U,$J,358.3,17331,1,5,0)
 ;;=5^Thrombocytosis, Essential
 ;;^UTILITY(U,$J,358.3,17331,2)
 ;;=^55344
 ;;^UTILITY(U,$J,358.3,17332,0)
 ;;=451.9^^88^937^121
 ;;^UTILITY(U,$J,358.3,17332,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,17332,1,4,0)
 ;;=4^451.9
 ;;^UTILITY(U,$J,358.3,17332,1,5,0)
 ;;=5^Thrombophlebitis 
 ;;^UTILITY(U,$J,358.3,17332,2)
 ;;=^93357
 ;;^UTILITY(U,$J,358.3,17333,0)
 ;;=446.6^^88^937^122
 ;;^UTILITY(U,$J,358.3,17333,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,17333,1,4,0)
 ;;=4^446.6
 ;;^UTILITY(U,$J,358.3,17333,1,5,0)
 ;;=5^Thrombotic Thrombocytopenic Purpura(Ttp)
 ;;^UTILITY(U,$J,358.3,17333,2)
 ;;=^119061
 ;;^UTILITY(U,$J,358.3,17334,0)
 ;;=286.4^^88^937^125
 ;;^UTILITY(U,$J,358.3,17334,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,17334,1,4,0)
 ;;=4^286.4
 ;;^UTILITY(U,$J,358.3,17334,1,5,0)
 ;;=5^Von Willebrand's Disease
 ;;^UTILITY(U,$J,358.3,17334,2)
 ;;=^127267
 ;;^UTILITY(U,$J,358.3,17335,0)
 ;;=204.00^^88^937^1
 ;;^UTILITY(U,$J,358.3,17335,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,17335,1,4,0)
 ;;=4^204.00
 ;;^UTILITY(U,$J,358.3,17335,1,5,0)
 ;;=5^ALL w/o Remission
 ;;^UTILITY(U,$J,358.3,17335,2)
 ;;=^267521
 ;;^UTILITY(U,$J,358.3,17336,0)
 ;;=204.01^^88^937^3
 ;;^UTILITY(U,$J,358.3,17336,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,17336,1,4,0)
 ;;=4^204.01
 ;;^UTILITY(U,$J,358.3,17336,1,5,0)
 ;;=5^ALL,In Remission
 ;;^UTILITY(U,$J,358.3,17336,2)
 ;;=^267522
 ;;^UTILITY(U,$J,358.3,17337,0)
 ;;=204.10^^88^937^16
 ;;^UTILITY(U,$J,358.3,17337,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,17337,1,4,0)
 ;;=4^204.10
 ;;^UTILITY(U,$J,358.3,17337,1,5,0)
 ;;=5^CLL w/o Remission
 ;;^UTILITY(U,$J,358.3,17337,2)
 ;;=^267523
 ;;^UTILITY(U,$J,358.3,17338,0)
 ;;=204.11^^88^937^18
 ;;^UTILITY(U,$J,358.3,17338,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,17338,1,4,0)
 ;;=4^204.11
 ;;^UTILITY(U,$J,358.3,17338,1,5,0)
 ;;=5^CLL,In Remission
 ;;^UTILITY(U,$J,358.3,17338,2)
 ;;=^267524
 ;;^UTILITY(U,$J,358.3,17339,0)
 ;;=201.90^^88^937^83
 ;;^UTILITY(U,$J,358.3,17339,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,17339,1,4,0)
 ;;=4^201.90
 ;;^UTILITY(U,$J,358.3,17339,1,5,0)
 ;;=5^Hodgkin's Lymphoma, Unpsec Type & Site
 ;;^UTILITY(U,$J,358.3,17339,2)
 ;;=^267430
 ;;^UTILITY(U,$J,358.3,17340,0)
 ;;=785.6^^88^937^89
 ;;^UTILITY(U,$J,358.3,17340,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,17340,1,4,0)
 ;;=4^785.6
 ;;^UTILITY(U,$J,358.3,17340,1,5,0)
 ;;=5^Lymphadenopathy
 ;;^UTILITY(U,$J,358.3,17340,2)
 ;;=^72368
 ;;^UTILITY(U,$J,358.3,17341,0)
 ;;=200.20^^88^937^90
 ;;^UTILITY(U,$J,358.3,17341,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,17341,1,4,0)
 ;;=4^200.20
 ;;^UTILITY(U,$J,358.3,17341,1,5,0)
 ;;=5^Lymphoma,Burkitt's,Site Unspec
 ;;^UTILITY(U,$J,358.3,17341,2)
 ;;=^17529
 ;;^UTILITY(U,$J,358.3,17342,0)
 ;;=202.00^^88^937^92
 ;;^UTILITY(U,$J,358.3,17342,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,17342,1,4,0)
 ;;=4^202.00
 ;;^UTILITY(U,$J,358.3,17342,1,5,0)
 ;;=5^Lymphoma,Low-Grade,Site Unspec
 ;;^UTILITY(U,$J,358.3,17342,2)
 ;;=^72606
 ;;^UTILITY(U,$J,358.3,17343,0)
 ;;=200.10^^88^937^91
 ;;^UTILITY(U,$J,358.3,17343,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,17343,1,4,0)
 ;;=4^200.10
 ;;^UTILITY(U,$J,358.3,17343,1,5,0)
 ;;=5^Lymphoma,Int or High Grade,Site Unspec
 ;;^UTILITY(U,$J,358.3,17343,2)
 ;;=^175886
 ;;^UTILITY(U,$J,358.3,17344,0)
 ;;=273.3^^88^937^93
 ;;^UTILITY(U,$J,358.3,17344,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,17344,1,4,0)
 ;;=4^273.3
 ;;^UTILITY(U,$J,358.3,17344,1,5,0)
 ;;=5^Macroglobulinemia
 ;;^UTILITY(U,$J,358.3,17344,2)
 ;;=^73013
 ;;^UTILITY(U,$J,358.3,17345,0)
 ;;=203.00^^88^937^103
 ;;^UTILITY(U,$J,358.3,17345,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,17345,1,4,0)
 ;;=4^203.00
 ;;^UTILITY(U,$J,358.3,17345,1,5,0)
 ;;=5^Multiple Myeloma w/o Remission
 ;;^UTILITY(U,$J,358.3,17345,2)
 ;;=^267514
 ;;^UTILITY(U,$J,358.3,17346,0)
 ;;=203.01^^88^937^105
 ;;^UTILITY(U,$J,358.3,17346,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,17346,1,4,0)
 ;;=4^203.01
 ;;^UTILITY(U,$J,358.3,17346,1,5,0)
 ;;=5^Multiple Myeloma,In Remission
 ;;^UTILITY(U,$J,358.3,17346,2)
 ;;=^267515
 ;;^UTILITY(U,$J,358.3,17347,0)
 ;;=238.6^^88^937^108
 ;;^UTILITY(U,$J,358.3,17347,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,17347,1,4,0)
 ;;=4^238.6
 ;;^UTILITY(U,$J,358.3,17347,1,5,0)
 ;;=5^Plasmacytoma NOS
 ;;^UTILITY(U,$J,358.3,17347,2)
 ;;=^81973
 ;;^UTILITY(U,$J,358.3,17348,0)
 ;;=205.00^^88^937^4
 ;;^UTILITY(U,$J,358.3,17348,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,17348,1,4,0)
 ;;=4^205.00
 ;;^UTILITY(U,$J,358.3,17348,1,5,0)
 ;;=5^AML w/o Remission
 ;;^UTILITY(U,$J,358.3,17348,2)
 ;;=^267531
 ;;^UTILITY(U,$J,358.3,17349,0)
 ;;=205.01^^88^937^6
 ;;^UTILITY(U,$J,358.3,17349,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,17349,1,4,0)
 ;;=4^205.01
 ;;^UTILITY(U,$J,358.3,17349,1,5,0)
 ;;=5^AML,In Remission
 ;;^UTILITY(U,$J,358.3,17349,2)
 ;;=^267532
 ;;^UTILITY(U,$J,358.3,17350,0)
 ;;=205.10^^88^937^19
 ;;^UTILITY(U,$J,358.3,17350,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,17350,1,4,0)
 ;;=4^205.10
 ;;^UTILITY(U,$J,358.3,17350,1,5,0)
 ;;=5^CML w/o Remission
 ;;^UTILITY(U,$J,358.3,17350,2)
 ;;=^267533
 ;;^UTILITY(U,$J,358.3,17351,0)
 ;;=205.11^^88^937^21
 ;;^UTILITY(U,$J,358.3,17351,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,17351,1,4,0)
 ;;=4^205.11
 ;;^UTILITY(U,$J,358.3,17351,1,5,0)
 ;;=5^CML,In Remission
 ;;^UTILITY(U,$J,358.3,17351,2)
 ;;=^267534
 ;;^UTILITY(U,$J,358.3,17352,0)
 ;;=289.0^^88^937^55
 ;;^UTILITY(U,$J,358.3,17352,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,17352,1,4,0)
 ;;=4^289.0
 ;;^UTILITY(U,$J,358.3,17352,1,5,0)
 ;;=5^Erthryocytosis, Secondary
 ;;^UTILITY(U,$J,358.3,17352,2)
 ;;=^186856
 ;;^UTILITY(U,$J,358.3,17353,0)
 ;;=238.4^^88^937^109
 ;;^UTILITY(U,$J,358.3,17353,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,17353,1,4,0)
 ;;=4^238.4
 ;;^UTILITY(U,$J,358.3,17353,1,5,0)
 ;;=5^Polycytheria Rubra Vera
